Pfizer And BioNTech Provide Update On mRNA-based Combination Vaccine Program Against Influenza And COVID-19: Says In A Phase 3 Trial, Vaccine Candidate Met One Of Its Two Primary Immunogenicity Objectives
Author: Benzinga Newsdesk | August 16, 2024 06:50am
The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines.
The companies are evaluating adjustments to the candidate and will discuss next steps with health authorities.
Pfizer also provides update on its separate Phase 2 second-generation trivalent influenza mRNA vaccine trial which showed encouraging data demonstrating robust immunogenicity against all strains compared to a standard of care influenza vaccine.
Posted In: BNTX PFE
